Background. Previous studies indicate that seasonal variation affects daily physical activity (PA), but none have investigated this relationship in individuals with heart failure (HF) who also have implanted cardioverter defibrillators and cardiac resynchronization therapy (ICD/CRT) devices. The purpose of the present study was to determine if seasonal variation in temperature affects daily PA in patients with HF and ICD/CRTs. Patients and methods: Secondary analysis of data from 16 subjects with HF and Medtronic® ICD/CRT devices enrolled in a randomized trial investigating interventions to improve daily PA. Due to the rolling study enrollment, daily PA data for all subjects were not available for the entire time frame and were divided into two groups. Determination of seasonal variation of daily PA was determined using visual analysis of daily PA plotted with average temperature, autocorrelation, visual analysis of seasonal subseries plots and boxplot analysis, as well as Wilcoxon signed-rank tests. Results. Subjects 1-8 demonstrated the greatest differences in daily PA during periods of seasonal transition whereas subjects 9-16 demonstrated the greatest variation in daily PA with greatest seasonal temperature difference. Wilcoxon signed-rank testing of the lowest and highest months for daily PA revealed median differences of 0.30 (p = 0.050) and 0.36 hours (p = 0.036) for subjects 1-8 and 9-16, with effect sizes of 0.69 and 0.74, respectively. Conclusions. Seasonal variation in mean temperature appears to affect daily PA in individuals with HF and ICD/CRT devices by a magnitude of 0.30-0.36 hours, which may need to be accounted for in future research investigating interventions to improve daily PA.
Cardiac resynchronization therapy, Daily physical activity, Heart failure, Implanted cardioverter defibrillator
Financial support: This study was funded by the Medtronic Cardiac
Rhythm and Heart Failure External Research Program. All decisions
related to study design, data collection, analysis, interpretation, and
manuscript preparation were that of the authors. Medtronic review
of the manuscript was strictly related to accurate representation/
description of Medtronic products.
Related Content In Interventional cardiology
The Coronary Sinus Reducer – Clinical Evidence and New Perspectives On An Emerging Tool in the Treatment of Refractory Angina
Heart International. 2020;14(1):Online ahead of journal publication
Refractory angina pectoris is a chronic disabling condition affecting an increasing number of patients (10–15%) with severe ischaemic heart disease.1 It is generally defined as the presence of debilitating angina due to severe and/or diffuse coronary artery disease (CAD), despite optimal medical therapy and with no option for further percutaneous or surgical revascularisation procedures. As […]
Clopidogrel-induced Pill Oesophagitis
Heart International. 2020;14(1): Online ahead of journal publication.
Antiplatelet agents are routinely given to prevent thrombosis of coronary stents.1 When antiplatelet drugs are not given before percutaneous coronary intervention (PCI), they may be given on the table during PCI.1 Ingestion of pills while supine on the catheterisation table often causes mild dysphagia and discomfort but, rarely, it can cause a more serious event. […]
Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?
Heart International. 2020;14(1): Online ahead of journal publication
Coronary artery disease (CAD), due to development of atherosclerotic plaques, remains a leading cause of morbidity and mortality. If unstable or clinically significant, these are frequently treated with percutaneous coronary intervention (PCI), typically involving balloon angioplasty and implantation of a metallic drug-eluting stent (DES).1 Coronary stents have substantially evolved since their first use in the 1980s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!